BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

316 related articles for article (PubMed ID: 15637389)

  • 1. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.
    Dannenberg AJ; Lippman SM; Mann JR; Subbaramaiah K; DuBois RN
    J Clin Oncol; 2005 Jan; 23(2):254-66. PubMed ID: 15637389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.
    Dannenberg AJ; Altorki NK; Boyle JO; Dang C; Howe LR; Weksler BB; Subbaramaiah K
    Lancet Oncol; 2001 Sep; 2(9):544-51. PubMed ID: 11905709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of colorectal cancer through inhibition of cyclooxygenase-2.
    Dannenberg AJ; Zakim D
    Semin Oncol; 1999 Oct; 26(5):499-504. PubMed ID: 10528897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular targeting therapy for pancreatic cancer.
    Xiong HQ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S69-77. PubMed ID: 15316751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.
    Chun KS; Surh YJ
    Biochem Pharmacol; 2004 Sep; 68(6):1089-100. PubMed ID: 15313405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?
    Koga H
    Cancer; 2003 Aug; 98(4):661-7. PubMed ID: 12910508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifaceted roles of cyclooxygenase-2 in lung cancer.
    Riedl K; Krysan K; Põld M; Dalwadi H; Heuze-Vourc'h N; Dohadwala M; Liu M; Cui X; Figlin R; Mao JT; Strieter R; Sharma S; Dubinett SM
    Drug Resist Updat; 2004 Jun; 7(3):169-84. PubMed ID: 15296859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review).
    Badawi AF; Badr MZ
    Int J Oncol; 2002 Jun; 20(6):1109-22. PubMed ID: 12011987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) expression in human pituitary macroadenomas.
    Bloomer CW; Kenyon L; Hammond E; Hyslop T; Andrews DW; Curran WJ; Dicker AP
    Am J Clin Oncol; 2003 Aug; 26(4):S75-80. PubMed ID: 12902861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor-induced cyclooxygenase-2 expression is mediated through phosphatidylinositol-3 kinase, not mitogen-activated protein/extracellular signal-regulated kinase kinase, in recurrent respiratory papillomas.
    Wu R; Abramson AL; Shikowitz MJ; Dannenberg AJ; Steinberg BM
    Clin Cancer Res; 2005 Sep; 11(17):6155-61. PubMed ID: 16144915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COX-2: a target for prevention and treatment of esophageal cancer.
    Altorki N
    J Surg Res; 2004 Mar; 117(1):114-20. PubMed ID: 15013721
    [No Abstract]   [Full Text] [Related]  

  • 13. Signaling through the epidermal growth factor receptor during the development of malignancy.
    Grandis JR; Sok JC
    Pharmacol Ther; 2004 Apr; 102(1):37-46. PubMed ID: 15056497
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
    Narayanan BA; Reddy BS; Bosland MC; Nargi D; Horton L; Randolph C; Narayanan NK
    Clin Cancer Res; 2007 Oct; 13(19):5965-73. PubMed ID: 17908994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention.
    Kashfi K; Rigas B
    Biochem Pharmacol; 2005 Oct; 70(7):969-86. PubMed ID: 15949789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polyamines and cancer: old molecules, new understanding.
    Gerner EW; Meyskens FL
    Nat Rev Cancer; 2004 Oct; 4(10):781-92. PubMed ID: 15510159
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune restoration in head and neck cancer patients via cyclooxygenase inhibition: an update.
    Lang S; Zeidler R
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):41-8. PubMed ID: 14552703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy.
    Romano M; Claria J
    FASEB J; 2003 Nov; 17(14):1986-95. PubMed ID: 14597668
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cyclooxygenase 2 inhibitors and cancer chemoprevention].
    Masmoudi A; Le Chevalier T; Sabatier L; Soria JC
    Bull Cancer; 2004 May; 91 Spec No():S77-84. PubMed ID: 15239334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR as a target: rationale for therapy.
    Wujcik D
    Semin Oncol Nurs; 2006 Feb; 22(1 Suppl 1):5-9. PubMed ID: 16616281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.